No headlines found.
Harrow Announces Nashville Expansion
Business Wire (Wed, 25-Sep 12:02 PM ET)
Harrow to Present at Three Investor Conferences in September in New York
Business Wire (Tue, 3-Sep 7:00 AM ET)
Harrow Announces Second Quarter 2024 Financial Results
Business Wire (Wed, 7-Aug 4:01 PM ET)
Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye Disease
Business Wire (Mon, 29-Jul 8:00 AM ET)
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
Business Wire (Thu, 25-Jul 7:00 AM ET)
Harrow to Attend 2024 ASRS Annual Meeting
Business Wire (Fri, 12-Jul 7:00 AM ET)
Business Wire (Tue, 9-Jul 7:00 AM ET)
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
Harrow trades on the NASDAQ stock market under the symbol HROW.
As of September 27, 2024, HROW stock price declined to $43.76 with 109,730 million shares trading.
HROW has a beta of 1.56, meaning it tends to be more sensitive to market movements. HROW has a correlation of 0.06 to the broad based SPY ETF.
HROW has a market cap of $1.55 billion. This is considered a Small Cap stock.
Last quarter Harrow reported $49 million in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-181,000 and exceeded earnings estimates by $.01.
In the last 3 years, HROW traded as high as $47.55 and as low as $5.40.
The top ETF exchange traded funds that HROW belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
HROW has outperformed the market in the last year with a price return of +211.9% while the SPY ETF gained +35.9%. HROW has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +105.1% and +4.0%, respectively, while the SPY returned +5.2% and +2.6%, respectively.
HROW support price is $42.78 and resistance is $45.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HROW shares will trade within this expected range on the day.